{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:15:38Z","timestamp":1792721738731,"version":"4.5.0"},"reference-count":72,"publisher":"Journal of Biological Methods","issue":"5","license":[{"start":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T00:00:00Z","timestamp":1674864000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HPR"],"abstract":"<jats:p>Purpose of Review\nThe present investigation is a comprehensive review regarding the use of Suvorexant for insomnia treatment. It covers the background, pathophysiology, and significance of addressing insomnia, the pharmaceutical details of Suvorexant, and its safety, efficacy, and implications in treating insomnia. We further discuss Suvorexant&amp;rsquo;s role in targeting insomnia with other comorbidities.\nRecent Findings\nInsomnia refers to poor quality and\/or quantity of sleep. While there are many existing treatments such as benzodiazepines, melatonin agonists, TCAs, and atypical antipsychotics used to target various receptors involved in normal induction and maintenance of sleep, Suvorexant is an antagonist that specifically targets orexin receptors. Recent clinical studies suggest that Suvorexant is both clinically safe and effective. Quantity and quality of sleep are measured in various ways, yet the consensus points towards Suvorexant&amp;rsquo;s effectiveness in improving sleep time, onset, latency, and quality compared to placebo. In addition to helping improve isolated insomnia, Suvorexant helps improve sleep in patients that have other comorbidities such as obstructive sleep apnea, Alzheimer&amp;rsquo;s disease, dementia, acute stroke, and delirium. While Suvorexant is safe, there are still adverse effects associated with the drug that needs to be considered. The most common adverse effects include dizziness, somnolence, headaches, and cognitive impairment.\nSummary\nInsomnia is a major public health concern that affects many people worldwide and has been linked to many adverse health outcomes. While there are existing treatments that target different receptors and pathways of normal sleep induction and maintenance, Suvorexant is a novel drug that targets dual orexin receptors. Its safety and efficacy, mechanism of action, pharmacokinetic parameters, and relative lack of rebound and withdrawal effects render suvorexant a reliable choice for the treatment of insomnia.<\/jats:p>","DOI":"10.52965\/001c.67898","type":"journal-article","created":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T13:14:36Z","timestamp":1674911676000},"page":"1","source":"Crossref","is-referenced-by-count":14,"title":["Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the \u00a0 Management of Insomnia"],"prefix":"10.14440","volume":"10","author":[{"given":"Andrew","family":"H. Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"R. Burroughs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"P. Falgoust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamal","family":"Hasoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Hunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juyeon","family":"Kakazu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"M. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"D. Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latha","family":"Ganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5574","published-online":{"date-parts":[[2023,1,28]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1176\/ajp.136.10.1257","article-title":"Prevalence of sleep disorders in the Los Angeles metropolitan area","volume":"136","author":"E O Bixler","year":"1979","journal-title":"American Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0002-953X","issn-type":"print"},{"issue":"1","key":"ref2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jsmc.2016.10.012","article-title":"Sleep, Health, and Society","volume":"12","author":"Michael A. Grandner","year":"2017","journal-title":"Sleep Medicine Clinics","ISSN":"https:\/\/id.crossref.org\/issn\/1556-407X","issn-type":"print"},{"issue":"3","key":"ref3","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/psy.0000000000000294","article-title":"A biobehavioral framework to address the emerging challenge of multimorbidity","volume":"78","author":"Jerry Suls","year":"2016","journal-title":"Psychosomatic Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3174","issn-type":"print"},{"issue":"1","key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.12876","article-title":"Does insomnia predict a high risk of cancer? A systematic review and meta-analysis of cohort studies","volume":"29","author":"Tingting Shi","year":"2020","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"},{"issue":"2","key":"ref5","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1532-5415.1998.tb02533.x","article-title":"Sleep complaints in community-dwelling older persons: Prevalence, associated factors, and reported causes","volume":"46","author":"Stefania Maggi","year":"1998","journal-title":"Journal of the American Geriatrics Society","ISSN":"https:\/\/id.crossref.org\/issn\/0002-8614","issn-type":"print"},{"issue":"11","key":"ref6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1001\/jama.1989.03430110069030","article-title":"Epidemiologic Study of Sleep Disturbances and Psychiatric Disorders: An Opportunity for Prevention?","volume":"262","author":"Daniel E. Ford","year":"1989","journal-title":"JAMA","ISSN":"https:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"issue":"6","key":"ref7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1093\/sleep\/18.6.425","article-title":"Sleep complaints among elderly persons: An epidemiologic study of three communities","volume":"18","author":"Daniel J. Foley","year":"1995","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9109","issn-type":"print"},{"issue":"1","key":"ref8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.5694\/j.1326-5377.1995.tb138406.x","article-title":"Insomnia in the elderly: Its prevalence and correlates in the general population","volume":"162","author":"Scott Henderson","year":"1995","journal-title":"Medical Journal of Australia","ISSN":"https:\/\/id.crossref.org\/issn\/0025-729X","issn-type":"print"},{"issue":"7","key":"ref9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/ijerph14070701","article-title":"Association between excessive use of mobile phone and insomnia and depression among Japanese adolescents","volume":"14","author":"Haruka Tamura","year":"2017","journal-title":"International Journal of Environmental Research and Public Health","ISSN":"https:\/\/id.crossref.org\/issn\/1660-4601","issn-type":"print"},{"issue":"4","key":"ref10","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1378\/chest.14-1617","article-title":"The pathophysiology of insomnia","volume":"147","author":"Jessica C. Levenson","year":"2015","journal-title":"Chest","ISSN":"https:\/\/id.crossref.org\/issn\/0012-3692","issn-type":"print"},{"issue":"3","key":"ref11","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.mcna.2014.01.008","article-title":"Insomnia","volume":"98","author":"Eliza L. Sutton","year":"2014","journal-title":"Medical Clinics of North America","ISSN":"https:\/\/id.crossref.org\/issn\/0025-7125","issn-type":"print"},{"issue":"1","key":"ref12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2337\/diaspect.29.1.5","article-title":"Physiology of sleep","volume":"29","author":"David W. Carley","year":"2016","journal-title":"Diabetes Spectrum","ISSN":"https:\/\/id.crossref.org\/issn\/1040-9165","issn-type":"print"},{"key":"ref13","article-title":"Insomnia, Chronic","author":"H. Kaur","year":"2018"},{"issue":"1","key":"ref14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1146\/annurev-pharmtox-010510-100528","article-title":"Orexin receptors: Pharmacology and therapeutic opportunities","volume":"51","author":"Thomas E. Scammell","year":"2011","journal-title":"Annual Review of Pharmacology and Toxicology","ISSN":"https:\/\/id.crossref.org\/issn\/0362-1642","issn-type":"print"},{"issue":"1","key":"ref15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3390\/ijms17010050","article-title":"Pharmacotherapy treatment options for insomnia: A primer for clinicians","volume":"17","author":"Gregory M. Asnis","year":"2015","journal-title":"International Journal of Molecular Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/1422-0067","issn-type":"print"},{"key":"ref16","article-title":"Pharmacological Treatment of Insomnia","author":"J.D. Lie"},{"key":"ref17","article-title":"Triazolam | C17H12Cl2N4 - PubChem"},{"issue":"12","key":"ref18","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2165\/00023210-200519120-00007","article-title":"Ramelteon","volume":"19","author":"Adam McGechan","year":"2005","journal-title":"CNS Drugs","ISSN":"https:\/\/id.crossref.org\/issn\/1172-7047","issn-type":"print"},{"key":"ref19","article-title":"Doxepin - StatPearls - NCBI Bookshelf","author":"A. Almasi"},{"key":"ref20","article-title":"HIGHLIGHTS OF PRESCRIBING INFORMATION"},{"key":"ref21","year":"2014","unstructured":"29. U.S. Food and Drug Administration, Merck & Co. Inc. BELSOMRA\u00ae (Suvorexant).; 2014. doi:Reference ID: 3610408"},{"issue":"5 suppl","key":"ref22","doi-asserted-by":"publisher","DOI":"10.5664\/jcsm.26929","article-title":"Insomnia: Definition, prevalence, etiology, and consequences","volume":"3","author":"Thomas Roth","year":"2007","journal-title":"Journal of Clinical Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9389","issn-type":"print"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/nss.s76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia-critical appraisal of suvorexant","volume":"8","author":"Jessica L. Norman","year":"2016","journal-title":"Nature and Science of Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/1179-1608","issn-type":"print"},{"key":"ref24","article-title":"Suvorexant (Belsomra) for insomnia","author":"A.R. Gauld","year":"2016","journal-title":"American Family Physician"},{"issue":"12","key":"ref25","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/ijcp.12568","article-title":"Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"L. Citrome","year":"2014","journal-title":"International Journal of Clinical Practice","ISSN":"https:\/\/id.crossref.org\/issn\/1368-5031","issn-type":"print"},{"key":"ref26","year":"2014","unstructured":"33. U.S. Food and Drug Administration, Merck & Co. Inc. BELSOMRA\u00ae (Suvorexant).; 2014. doi:Reference ID: 3610408"},{"issue":"8","key":"ref27","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.5664\/jcsm.7282","article-title":"An update on dual orexin receptor antagonists and their potential role in insomnia therapeutics","volume":"14","author":"Kayla Janto","year":"2018","journal-title":"Journal of Clinical Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1550-9389","issn-type":"print"},{"issue":"12","key":"ref28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1111\/ijcp.12568","article-title":"Suvorexant for insomnia: A systematic review of the efficacy and safety profile for this newly approved hypnotic - What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?","volume":"68","author":"L. Citrome","year":"2014","journal-title":"International Journal of Clinical Practice","ISSN":"https:\/\/id.crossref.org\/issn\/1368-5031","issn-type":"print"},{"key":"ref29","article-title":"Suvorexant (Belsomra) for insomnia","author":"A.R. Gauld","year":"2016","journal-title":"American Family Physician"},{"issue":"1","key":"ref30","doi-asserted-by":"publisher","first-page":"059","DOI":"10.1310\/hpj5001-059","article-title":"Suvorexant","volume":"50","author":"Dennis Cada","year":"2015","journal-title":"Hospital Pharmacy","ISSN":"https:\/\/id.crossref.org\/issn\/0018-5787","issn-type":"print"},{"key":"ref31","isbn-type":"print","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/978-3-319-23078-8_17","article-title":"A new class of hypnotic compounds for the treatment of insomnia: The dual orexin receptor antagonists","author":"Jason M. Uslaner","year":"2015","ISBN":"https:\/\/id.crossref.org\/isbn\/9783319230771","journal-title":"Orexin and Sleep"},{"issue":"6","key":"ref32","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/17512433.2014.966813","article-title":"Suvorexant for the treatment of insomnia","volume":"7","author":"Laura H Jacobson","year":"2014","journal-title":"Expert Review of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1751-2433","issn-type":"print"},{"issue":"2","key":"ref33","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.jsmc.2008.02.001","article-title":"Insomnia: Prevalence, Impact, Pathogenesis, Differential Diagnosis, and Evaluation","volume":"3","author":"Evelyn Mai","year":"2008","journal-title":"Sleep Medicine Clinics","ISSN":"https:\/\/id.crossref.org\/issn\/1556-407X","issn-type":"print"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/7854_2016_47","article-title":"Orexin OX2 receptor antagonists as sleep aids","author":"Laura H. Jacobson","year":"2017","journal-title":"Current Topics in Behavioral Neurosciences","ISSN":"https:\/\/id.crossref.org\/issn\/1866-3370","issn-type":"print"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sleep.2015.10.007","article-title":"Effects of suvorexant on sleep architecture and power spectral profile in patients with insomnia: Analysis of pooled phase 3 data","volume":"19","author":"Ellen Snyder","year":"2016","journal-title":"Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1389-9457","issn-type":"print"},{"issue":"1","key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2202-14-90","article-title":"The duration of sleep promoting efficacy by dual orexin receptor antagonists is dependent upon receptor occupancy threshold","volume":"14","author":"Anthony L Gotter","year":"2013","journal-title":"BMC Neuroscience","ISSN":"https:\/\/id.crossref.org\/issn\/1471-2202","issn-type":"print"},{"issue":"6","key":"ref37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1586\/17512433.2014.966813","article-title":"Suvorexant for the treatment of insomnia","volume":"7","author":"Laura H Jacobson","year":"2014","journal-title":"Expert Review of Clinical Pharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1751-2433","issn-type":"print"},{"issue":"5","key":"ref38","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/s1474-4422(14)70053-5","article-title":"Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: A phase 3 randomised, double-blind, placebo-controlled trial","volume":"13","author":"David Michelson","year":"2014","journal-title":"The Lancet Neurology","ISSN":"https:\/\/id.crossref.org\/issn\/1474-4422","issn-type":"print"},{"issue":"2","key":"ref39","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0976-500x.155496","article-title":"Suvorexant: The first orexin receptor antagonist to treat insomnia","volume":"6","author":"Ashok K. Dubey","year":"2015","journal-title":"Journal of Pharmacology and Pharmacotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2386","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","author":"Hong Sun","year":"2013","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"1","key":"ref41","doi-asserted-by":"publisher","first-page":"059","DOI":"10.1310\/hpj5001-059","article-title":"Suvorexant","volume":"50","author":"Dennis Cada","year":"2015","journal-title":"Hospital Pharmacy","ISSN":"https:\/\/id.crossref.org\/issn\/0018-5787","issn-type":"print"},{"issue":"5","key":"ref42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/2042098615595359","article-title":"Suvorexant in insomnia: efficacy, safety and place in therapy","volume":"6","author":"Danielle N. Rhyne","year":"2015","journal-title":"Therapeutic Advances in Drug Safety","ISSN":"https:\/\/id.crossref.org\/issn\/2042-0986","issn-type":"print"},{"issue":"2","key":"ref43","doi-asserted-by":"publisher","first-page":"118","DOI":"10.4103\/0976-500x.155496","article-title":"Suvorexant: The first orexin receptor antagonist to treat insomnia","volume":"6","author":"Ashok K. Dubey","year":"2015","journal-title":"Journal of Pharmacology and Pharmacotherapeutics","ISSN":"https:\/\/id.crossref.org\/issn\/0976-500X","issn-type":"print"},{"key":"ref44","article-title":"The impact and prevalence of chronic insomnia and other sleep disturbances associated with chronic illness","author":"S. Ancoli-Israel","year":"2006","journal-title":"American Journal of Managed Care"},{"key":"ref45","article-title":"THE SINGLE DOSE PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) PROFILES OF SUVOREXANT (MK-4305), A DUAL OREXIN RECEPTOR ANTAGONIST, IN HEALTHY MALE SUBJECTS","author":"H. Sun","year":"2012","journal-title":"Clinical Pharmacology & Therapeutics"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.5665\/sleep.2386","article-title":"Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men","author":"Hong Sun","year":"2013","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"10","key":"ref47","doi-asserted-by":"publisher","first-page":"882","DOI":"10.3109\/00498254.2015.1129565","article-title":"<i>In vitro<\/i> and <i>in vivo<\/i> characterisation of the metabolism and disposition of suvorexant in humans","volume":"46","author":"Donghui Cui","year":"2016","journal-title":"Xenobiotica","ISSN":"https:\/\/id.crossref.org\/issn\/0049-8254","issn-type":"print"},{"issue":"1","key":"ref48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40268-018-0256-6","article-title":"Suvorexant (Belsomra\u00ae Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey","volume":"19","author":"Yuko Asai","year":"2018","journal-title":"Drugs in R&D","ISSN":"https:\/\/id.crossref.org\/issn\/1174-5886","issn-type":"print"},{"key":"ref49","article-title":"Efficacy and Safety of Suvorexant for the Treatment of Primary Insomnia among Chinese: A 6-Month Randomized Double-Blind Controlled Study","author":"B. Fan"},{"issue":"1","key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsx178","article-title":"Insight into reduction of wakefulness by suvorexant in patients with insomnia: Analysis of wake bouts","volume":"41","author":"Vladimir Svetnik","year":"2018","journal-title":"Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/0161-8105","issn-type":"print"},{"issue":"48","key":"ref51","doi-asserted-by":"publisher","first-page":"24353","DOI":"10.1073\/pnas.1907354116","article-title":"Distinct effects of orexin receptor antagonist and GABA <sub>A<\/sub> agonist on sleep and physical\/cognitive functions after forced awakening","volume":"116","author":"Jaehoon Seol","year":"2019","journal-title":"Proceedings of the National Academy of Sciences","ISSN":"https:\/\/id.crossref.org\/issn\/0027-8424","issn-type":"print"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.sleep.2018.09.010","article-title":"Effects of suvorexant on the Insomnia Severity Index in patients with insomnia: analysis of pooled phase 3 data","volume":"56","author":"W. Joseph Herring","year":"2019","journal-title":"Sleep Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/1389-9457","issn-type":"print"},{"issue":"9","key":"ref53","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1089\/cap.2016.0206","article-title":"Suvorexant for the Treatment of Insomnia in Adolescents","volume":"27","author":"Kentaro Kawabe","year":"2017","journal-title":"Journal of Child and Adolescent Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/1044-5463","issn-type":"print"},{"issue":"3","key":"ref54","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1080\/03007995.2019.1700361","article-title":"Real-world evidence of the safety and efficacy profile of suvorexant in elderly patients with insomnia: a sub-analysis of the post-marketing drug-use results survey in Japan","volume":"36","author":"Yuko Takeuchi","year":"2020","journal-title":"Current Medical Research and Opinion","ISSN":"https:\/\/id.crossref.org\/issn\/0300-7995","issn-type":"print"},{"issue":"2","key":"ref55","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: What we know and what we still need to learn","volume":"6","author":"Maurice M. Ohayon","year":"2002","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"issue":"11","key":"ref56","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00213-017-4573-1","article-title":"Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data","volume":"234","author":"W. Joseph Herring","year":"2017","journal-title":"Psychopharmacology","ISSN":"https:\/\/id.crossref.org\/issn\/0033-3158","issn-type":"print"},{"issue":"7","key":"ref57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s40261-018-0650-4","article-title":"Safety, Tolerability, and Pharmacokinetics of Suvorexant: A Randomized Rising-Dose Trial in Healthy Men","volume":"38","author":"Ka Lai Yee","year":"2018","journal-title":"Clinical Drug Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/1173-2563","issn-type":"print"},{"issue":"5","key":"ref58","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s40261-019-00764-x","article-title":"Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects","volume":"39","author":"Rebecca E. Wrishko","year":"2019","journal-title":"Clinical Drug Investigation","ISSN":"https:\/\/id.crossref.org\/issn\/1173-2563","issn-type":"print"},{"issue":"11","key":"ref59","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1080\/14740338.2019.1657091","article-title":"Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey","volume":"18","author":"Hideki Sano","year":"2019","journal-title":"Expert Opinion on Drug Safety","ISSN":"https:\/\/id.crossref.org\/issn\/1474-0338","issn-type":"print"},{"issue":"7","key":"ref60","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.jagp.2017.03.004","article-title":"Suvorexant in Elderly Patients with Insomnia: Pooled Analyses of Data from Phase III Randomized Controlled Clinical Trials","volume":"25","author":"W. Joseph Herring","year":"2017","journal-title":"American Journal of Geriatric Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1064-7481","issn-type":"print"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"809","DOI":"10.2147\/dddt.s197237","article-title":"Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience","volume":"13","author":"Takuma Matsumura","year":"2019","journal-title":"Drug Design, Development and Therapy","ISSN":"https:\/\/id.crossref.org\/issn\/1177-8881","issn-type":"print"},{"issue":"3","key":"ref62","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"W. Joseph Herring","year":"2020","journal-title":"Alzheimer's & Dementia","ISSN":"https:\/\/id.crossref.org\/issn\/1552-5260","issn-type":"print"},{"issue":"2","key":"ref63","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0004867417747402","article-title":"Suvorexant for the treatment of insomnia in patients with Alzheimer\u2019s disease","volume":"52","author":"Atsushi Hamuro","year":"2018","journal-title":"Australian & New Zealand Journal of Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/0004-8674","issn-type":"print"},{"issue":"1","key":"ref64","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.09.024","article-title":"Addition of Suvorexant to Ramelteon Therapy for Improved Sleep Quality with Reduced Delirium Risk in Acute Stroke Patients","volume":"28","author":"Kei Kawada","year":"2019","journal-title":"Journal of Stroke and Cerebrovascular Diseases","ISSN":"https:\/\/id.crossref.org\/issn\/1052-3057","issn-type":"print"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jcte.2018.12.006","article-title":"Improvement of glycemic control by treatment for insomnia with suvorexant in type 2 diabetes mellitus","volume":"15","author":"Norikazu Toi","year":"2019","journal-title":"Journal of Clinical & Translational Endocrinology","ISSN":"https:\/\/id.crossref.org\/issn\/2214-6237","issn-type":"print"},{"issue":"5","key":"ref66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1001\/archinternmed.2008.610","article-title":"The natural history of insomnia: a population-based 3-year longitudinal study","volume":"169","author":"Charles M. Morin","year":"2009","journal-title":"Archives of Internal Medicine","ISSN":"https:\/\/id.crossref.org\/issn\/0003-9926","issn-type":"print"},{"issue":"4","key":"ref67","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s12264-019-00447-9","article-title":"Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders","volume":"36","author":"Ying Han","year":"2019","journal-title":"Neuroscience Bulletin","ISSN":"https:\/\/id.crossref.org\/issn\/1673-7067","issn-type":"print"},{"issue":"10","key":"ref68","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1038\/nbt1014-968","article-title":"Insomniacs get new mechanism sleep drug Belsomra","volume":"32","author":"Cormac Sheridan","year":"2014","journal-title":"Nature Biotechnology","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0156","issn-type":"print"},{"key":"ref69","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2147\/nss.s76910","article-title":"Novel class of medications, orexin receptor antagonists, in the treatment of insomnia-critical appraisal of suvorexant","volume":"8","author":"Jessica L. Norman","year":"2016","journal-title":"Nature and Science of Sleep","ISSN":"https:\/\/id.crossref.org\/issn\/1179-1608","issn-type":"print"},{"issue":"3","key":"ref70","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/wps.20674","article-title":"The assessment and management of insomnia: an update","volume":"18","author":"Andrew D. Krystal","year":"2019","journal-title":"World Psychiatry","ISSN":"https:\/\/id.crossref.org\/issn\/1723-8617","issn-type":"print"},{"issue":"2","key":"ref71","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/smrv.2002.0186","article-title":"Epidemiology of insomnia: What we know and what we still need to learn","volume":"6","author":"Maurice M. Ohayon","year":"2002","journal-title":"Sleep Medicine Reviews","ISSN":"https:\/\/id.crossref.org\/issn\/1087-0792","issn-type":"print"},{"issue":"1","key":"ref72","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2869.2000.00178.x","article-title":"Prevalence of insomnia in a survey of 12 778 adults in France","volume":"9","author":"Damien Leger","year":"2000","journal-title":"Journal of Sleep Research","ISSN":"https:\/\/id.crossref.org\/issn\/0962-1105","issn-type":"print"}],"container-title":["Health Psychology Research"],"original-title":[],"link":[{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202504071740518c80c8765.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.healthpr.org\/uploads\/file\/asp\/202504071740518c80c8765.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T03:47:42Z","timestamp":1760413662000},"score":1,"resource":{"primary":{"URL":"https:\/\/healthpr.org\/journal\/HPR\/10\/5\/10.52965\/001c.67898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,28]]},"references-count":72,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,10,11]]}},"URL":"https:\/\/doi.org\/10.52965\/001c.67898","relation":{},"ISSN":["2420-8124"],"issn-type":[{"value":"2420-8124","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,28]]}}}